Navigation Links
Triple-negative breast cancer subtypes identified using microRNA
Date:2/7/2013

  • Triple-negative breast cancer is an aggressive form of breast cancer that has few treatment options;
  • This large-scale study shows that abnormal levels of small molecules called microRNA can be used to classify this malignancy into four subtypes;
  • The findings could lead to new ways to identify the best therapy for individual patients and to more effective therapies in the future.

COLUMBUS, Ohio A new, large-scale study of triple-negative breast cancer shows that small molecules called microRNA can be used to define four subtypes of this aggressive malignancy.

The findings, by researchers at The Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) working with collaborators in Italy, could lead to new screening methods, prognostic markers and perhaps new targeted treatments for this aggressive and often-fatal form of breast cancer.

The study is published in the journal PLOS ONE.

"The treatment of women with triple-negative breast cancer is challenging because this malignancy can be very different genetically from one patient to another," says co-senior investigator Dr. Charles Shapiro, director of Breast Medical Oncology and professor of internal medicine at the OSUCCC James.

"We believe these microRNA signatures define novel sub-sets of triple-negative breast cancer and offer new insights into the biology of the disease and better ways to treat these patients," Shapiro says.

The microRNAs that compose the signatures are involved in regulating cell growth, proliferation and survival, and in cell movement and migration.

"These findings strongly suggest that microRNAs play an important role in triple-negative breast cancer and might be used to better identify the most effective treatment for a patient's tumor," says co-senior investigator and researcher Dr. Kay Huebner, professor of molec
'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
2. Quantum dots deliver Vitamin D to tumors for possible inflammatory breast cancer treatment
3. In breast cancer metastasis, researchers identify possible drug target
4. Vitamin D holds promise in battling a deadly breast cancer, Saint Louis University researchers say
5. Does your job increase your breast cancer risk?
6. Breast cancer drug could halt other tumors
7. UCLA researchers to study depression in breast cancer survivors
8. Scientists unravel resistance to breast cancer treatment
9. High levels of DDT in breast milk
10. Breast milk promotes a different gut flora growth than infant formulas
11. New method provides fast, accurate, low cost analysis of BRCA gene mutations in breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Conn. , Jul. 31, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies such ... by introducing a common, uniform way to manage all ...
(Date:7/30/2015)... 30, 2015 Cellecta, Inc., a U.S.-based ... analysis and biomarker discovery, announced the release of ... targeting all human protein coding genes. CRISPR technology ... a gene,s function. Cellecta,s new Human Whole Genome ... tool so that researchers can investigate in a ...
(Date:7/27/2015)... , July 27, 2015   Zynx ... and experience-based clinical improvement solutions, today announced that ... is now available on Android smartphones and tablets. ... and post-care organizations can use ZynxCarebook to securely ... patient,s condition, streamline care transitions to other care ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... HOUSTON, Oct. 22, 2010 Researchers can spend entire ... efforts featured in the pages of Science , ... won,t be the case, though, for two junior faculty ... Jacinta Conrad and Jeff Rimer, both assistant ...
... LA Research conducted by scientists at LSU Health Sciences ... brain act as valves to turn the hormone that regulates ... may lead to advances in treatment for diseases like high ... The research is published in the November 1, 2010 issue ...
... received two grants from the California Institutefor Regenerative Medicine ... treating neurological diseases and liver failure. The goal of ... toward the development of potential therapies within the next ... successful, they could then be further prepared as potential ...
Cached Biology News:UH engineering professors featured in consecutive issues of Science 2UH engineering professors featured in consecutive issues of Science 3LSUHSC study IDs proteins regulating water retention in salt-sensitive hypertension 2UCSF stem-cell based-neurological, liver therapy strategies advanced 2UCSF stem-cell based-neurological, liver therapy strategies advanced 3UCSF stem-cell based-neurological, liver therapy strategies advanced 4
(Date:8/27/2015)... , Aug. 27, 2015  Neogen Corporation (NASDAQ: ... stock of United Kingdom -based Lab ... culture media and diagnostic systems. Lab ... a leading provider of microbial testing and diagnostic products ... markets. The company currently sells into more than 70 ...
(Date:8/27/2015)... -- HUYA Bioscience International (HUYA) today announced the sponsorship of ... HTLV-1, held this week at the University of Tokyo ... is to promote research on HTLV-1 and HTLV-1-associated diseases, ... research related to these fields to advance science, the ... to support this prestigious conference," said Mireille Gillings ...
(Date:8/27/2015)... ... August 27, 2015 , ... Proove ... new data on the relationship of genetics and hypertension at the International ... Disease in Vancouver, British Columbia, Canada. The event, which boasts an extensive overview ...
(Date:8/26/2015)... , Aug. 26, 2015  The Diabetes ... the University of Miami Miller School of Medicine, ... clinical trial to test for the first time ... successfully completed.  This FDA approved Phase I/II study ... transplantation and is an important first step toward ...
Breaking Biology Technology:Neogen acquires U.K.-based Lab M Holdings 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 2HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 3HUYA Bioscience International Sponsors Japan Society Of HTLV-1 Annual Meeting 4Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 2Proove Biosciences Presents Ground-Breaking Data on Genetics and Heart Disease at 20th World Congress on Heart Disease 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 2Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 3Diabetes Research Institute Successfully Transplants First Patient In Pilot BioHub Trial 4
... constant currency revenue growth of 12.9 percent,- Full year ... and improving profitability reflects success of strategic ... for fiscal year 2009, BATESVILLE, Ind., Nov. 10 ... financial results for its fiscal,fourth quarter ended September 30, ...
... Incorporated,(Nasdaq: SPEX ) reported that the Nasdaq Stock ... its common stock from the Nasdaq,Global Market to the ... trading on the Nasdaq Capital Market on November 11, ... three market tier designations for,Nasdaq-listed stocks, and presently includes ...
... Conference Call Today at 4:30 p.m. Eastern Time -, ... MDVN ) today reported on its corporate progress and ... "The third quarter represented another quarter of significant,achievement and ... partnering,agreement with Pfizer for Dimebon. This collaboration not only ...
Cached Biology Technology:Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19Spherix Transfers Stock Listing to Nasdaq Capital Market 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7Medivation Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8
... StabilZyme AP Conjugate Stabilizer is ... purified bovine protein and other non-toxic ... (4-Morpholine-ethanesulfonic acid), pH 5.5 6.5. ... of 0.02% methylisothiazolone and 0.02% bromonitrodioxane ...
... When nonspecific binding is a ... a variety of immobilized NeutrAvidin products ... streptavidin. NeutrAvidin is a modified avidin ... to provide a biotin-binding protein with ...
Cells are grown to a specified density and induced, when necessary. Protein expression samples are collected at 3 growth points and analyzed by SDS-PAGE/Coomassie....
... generated hybridomas against a large variety ... you are provided with personalized project ... lines developed by Covance remain exclusive ... hybridoma development project has four phases: ...
Biology Products: